Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 5
2001 3
2002 6
2003 2
2004 4
2005 1
2006 1
2007 3
2008 7
2009 5
2010 3
2011 6
2012 6
2013 5
2014 7
2015 3
2016 5
2017 5
2018 4
2019 10
2020 4
2021 3
2022 2
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer.
Adinolfi S, Patinen T, Jawahar Deen A, Pitkänen S, Härkönen J, Kansanen E, Küblbeck J, Levonen AL. Adinolfi S, et al. Among authors: levonen al. Redox Biol. 2023 Jul;63:102726. doi: 10.1016/j.redox.2023.102726. Epub 2023 Apr 29. Redox Biol. 2023. PMID: 37146513 Free PMC article. Review.
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.
Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT. Cuadrado A, et al. Among authors: levonen al. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. doi: 10.1038/s41573-018-0008-x. Nat Rev Drug Discov. 2019. PMID: 30610225 Review.
A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies.
Härkönen J, Pölönen P, Deen AJ, Selvarajan I, Teppo HR, Dimova EY, Kietzmann T, Ahtiainen M, Väyrynen JP, Väyrynen SA, Elomaa H, Tynkkynen N, Eklund T, Kuopio T, Talvitie EM, Taimen P, Kallajoki M, Kaikkonen MU, Heinäniemi M, Levonen AL. Härkönen J, et al. Among authors: levonen al. Redox Biol. 2023 May;61:102644. doi: 10.1016/j.redox.2023.102644. Epub 2023 Feb 27. Redox Biol. 2023. PMID: 36867945 Free PMC article.
Electrophilic metabolites targeting the KEAP1/NRF2 partnership.
Dinkova-Kostova AT, Hakomäki H, Levonen AL. Dinkova-Kostova AT, et al. Among authors: levonen al. Curr Opin Chem Biol. 2024 Feb;78:102425. doi: 10.1016/j.cbpa.2024.102425. Epub 2024 Jan 18. Curr Opin Chem Biol. 2024. PMID: 38241876 Free article. Review.
Regulation of stress signaling pathways by protein lipoxidation.
Patinen T, Adinolfi S, Cortés CC, Härkönen J, Jawahar Deen A, Levonen AL. Patinen T, et al. Among authors: levonen al. Redox Biol. 2019 May;23:101114. doi: 10.1016/j.redox.2019.101114. Epub 2019 Jan 16. Redox Biol. 2019. PMID: 30709792 Free PMC article. Review.
Dysregulation of the Keap1-Nrf2 pathway in cancer.
Leinonen HM, Kansanen E, Pölönen P, Heinäniemi M, Levonen AL. Leinonen HM, et al. Among authors: levonen al. Biochem Soc Trans. 2015 Aug;43(4):645-9. doi: 10.1042/BST20150048. Epub 2015 Aug 3. Biochem Soc Trans. 2015. PMID: 26551706 Review.
The EDCMET Project: Metabolic Effects of Endocrine Disruptors.
Küblbeck J, Vuorio T, Niskanen J, Fortino V, Braeuning A, Abass K, Rautio A, Hakkola J, Honkakoski P, Levonen AL. Küblbeck J, et al. Among authors: levonen al. Int J Mol Sci. 2020 Apr 24;21(8):3021. doi: 10.3390/ijms21083021. Int J Mol Sci. 2020. PMID: 32344727 Free PMC article. Review.
Role of the Keap1-Nrf2 pathway in cancer.
Leinonen HM, Kansanen E, Pölönen P, Heinäniemi M, Levonen AL. Leinonen HM, et al. Among authors: levonen al. Adv Cancer Res. 2014;122:281-320. doi: 10.1016/B978-0-12-420117-0.00008-6. Adv Cancer Res. 2014. PMID: 24974185 Review.
Keap1 as the redox sensor of the antioxidant response.
Sihvola V, Levonen AL. Sihvola V, et al. Among authors: levonen al. Arch Biochem Biophys. 2017 Mar 1;617:94-100. doi: 10.1016/j.abb.2016.10.010. Epub 2016 Oct 18. Arch Biochem Biophys. 2017. PMID: 27769838 Review.
Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ, Adinolfi S, Härkönen J, Patinen T, Liu X, Laitinen T, Takabe P, Kainulainen K, Pasonen-Seppänen S, Gawriyski LM, Arasu UT, Selvarajan I, Mäkinen P, Laitinen H, Kansanen E, Kaikkonen MU, Poso A, Varjosalo M, Levonen AL. Deen AJ, et al. Among authors: levonen al. Redox Biol. 2024 Feb;69:103031. doi: 10.1016/j.redox.2024.103031. Epub 2024 Jan 4. Redox Biol. 2024. PMID: 38184997 Free PMC article.
98 results